Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

Korábbi kezelés

• Patients receiving other antitumor therapies, such as chemotherapy, targeted therapy or radiotherapy;

Más betegség

• Patients have other primary malignant tumors;
• CRC patients with gastrointestinal perforation
• Patients with malignant bowel obstruction refractory to conservative management;
• Patients are allergic to the antitumor agents;

Egyéb

• Patients with recurrent CRC;
• Patients with distant metastases besides synchronous hepatic metastases (e.g., pulmonary, bone, or brain metastases);
• For patients with CRLM, the MDT consensus recommends a liver-first treatment strategy to avoid the risk of rapid hepatic lesion progression;
• Women pregnant, breastfeeding or planning to become pregnant;
• Patients with MSI-H/dMMR CRC.

• Age ≥ 18 years old;
• Histopathologically confirmed CRC adenocarcinoma;
• Locally advanced CRC confirmed as clinical T4 stage on CT/MRI imaging, with or without synchronous liver metastases;
• For patients with CRLM, hepatic tumor burden shall be lower than the burden of the primary colorectal lesion. Consequently, the multidisciplinary team (MDT) agree by consensus that CRC should be a priority target for treatment.
• No prior administration of chemotherapy, targeted therapy or radiotherapy for the current malignancy;
• Adequate haematological, heart, liver and renal functions are required, with the following specific criteria: white blood cell count≥4×109 /L, neutrophils≥1.5×109 /L, platelets≥100×10⁹ /L, haemoglobin≥100 g/L, total bilirubin≤34.2 μmol/L, aspartate aminotransferase≤100 IU/L, alanine aminotransferase≤100 IU/L, serum creatinine ≤133 μmol/L or creatinine clearance rate≥60 mL/min, and urine protein/creatinine<1;
• Estimated survival is more than 3 months;
• Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2;
• All the patients in this study are required to sign an informed consent form.

A regiszterben nem jelölt feltételek

• Study population:
• Patients who meet all inclusion criteria and none of the exclusion criteria are eligible for enrolment and study treatment.